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Abstract: Highly active antiretroviral therapy (HAART) has had a profound impact on 
  improving the long-term prognosis for individuals infected with human immunodeficiency virus 
(HIV). HAART has been available for close to two decades, and now a significant number of 
patients with access to HAART are over the age of 50 years. Many clinical studies have indicated 
that HIV infection, as well as components of HAART, can increase the risk in these individuals 
to a variety of noninfectious complications, including a risk to bone health. There is a significant 
need for detailed mechanistic analysis of the aging, HIV-infected population regarding the risk 
of HIV infection and therapy in order to maintain bone health. Insights from basic mechanistic 
studies will help to shed light on the role of HIV infection and the components of HAART that 
impact bone health, and will help in identifying preventative countermeasures, particularly for 
individuals 50 years of age and older.
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Introduction
There has been little research into how human immunodeficiency virus (HIV) infec-
tion and the aging process together influence the health and well being of infected 
individuals, which poses many challenges for health care providers, as well as for 
policy makers.1 Given the advent of highly active antiretroviral therapy (HAART) 
about two decades ago, HIV-infected individuals have a significantly improved 
long-term survival, with many of those affected now aged 50 years and older. HIV 
infection and its treatment have increasingly led to concerns over comorbidities, 
such as   cardiovascular disease, cancer, depression, dementia, and bone mineral 
density loss. Such concerns parallel the general concerns regarding the health and 
well being in the aging population. In the US, data from the Centers for Disease 
Control have indicated that individuals aged 50 years and older represent 29% 
of those living with acquired immunodeficiency syndrome (AIDS), 24% of those 
living with HIV/AIDS, and 15% of new HIV/AIDS diagnoses.2 The rates among 
African-Americans and Hispanic-Americans are 12 times and five times greater, 
respectively. It has been estimated that by 2015, 50% of individuals living with 
HIV/AIDS will be 50 years of age or older.3 These epidemiologic data indicate that 
the HIV epidemic in the US and other countries with access to HAART will cause 
a change in the nature of HIV clinics, changing the focus from health concerns 
in younger patients to a broader age range, with an increasing focus on geriatric 
issues, including issues relating to bone health.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Basic bone biology and pathology
Bone is a dynamic tissue in the body that is formed and 
maintained by two cell types, ie, osteoblasts (which form 
bone) and osteoclasts (which resorb bone). There is an 
extensive cell-signaling network between osteoblasts and 
osteoclasts required for maintaining the balance of activities 
of these two cell types that is crucial for bone remodeling 
and bone health. Direct signals between bone cells have 
recently been implicated as being important for regulating 
bone remodeling.4–6 For instance, osteoclasts can initiate 
bone formation via signaling to osteoblasts, independent 
of their ability to resorb bone.7,8 It has been demonstrated 
in patients with autosomal dominant osteopetrosis Type II 
that the number of osteoclasts, but not their activity, controls 
bone formation.9 In contrast, osteoblasts regulate osteoclast 
differentiation by expressing two factors that are necessary 
and sufficient for osteoclast formation, ie, M-CSF10 and 
RANKL.11
Measurement of bone health
Several different methods are used to measure bone density. 
These include dual-energy X-ray absorptiometry, quantita-
tive computed tomography, and quantitative ultrasound. 
While dual-energy X-ray absorptiometry is typically the 
most common method used and is considered the gold 
standard for measuring bone density, quantitative computed 
tomography and quantitative ultrasound can provide other 
useful information. Quantitative computed tomography 
provides measurements of cortical and trabecular volumetric 
bone mineral density, and studies have found using quan-
titative computed tomography that individual subregions 
of trabecular and cortical compartments are independent 
predictors of hip fracture and have differential responses 
to osteoporosis treatments.12,13 Quantitative ultrasound can 
provide further information on bone fragility and fracture 
risk, particularly in postmenopausal women.14–16 Both the 
spine and femur are common sites of analysis, and both 
regions contain cortical bone (dense outer shell) as well as 
trabecular bone (interconnecting sponge-like bony sheets), 
although the spine has relatively more cancellous bone, which 
can undergo the highest rate of bone turnover. Osteopenia 
and osteoporosis are diagnosed by comparing bone mineral 
density of an individual with expected normal values. The 
T score represents the number of standard deviation differ-
ences between an individual’s bone mineral density versus 
that of the mean of the population at peak bone mass. The T 
score creates a foundation for comparison of individuals as 
having osteopenia or osteoporosis, and can be of practical 
utility in predicting subsequent risk of fracture in men and 
women 50 years of age and older.
A recent report has described the use of the World 
Health Organization’s FRAX equation as a first-line screen-
ing of bone metabolism alteration in the HIV-infected 
population.17,18 FRAX is a computer-based algorithm that 
calculates the 10-year probability of fractures in men and 
women on the basis of classic risk factors alone or by inte-
gration with bone mineral density, which is measured by 
dual-energy X-ray absorptiometry. The FRAX algorithm 
has been proposed as a screening tool for HIV-positive 
individuals to identify those who have an increased clini-
cal risk of fractures and for where bone mineral density 
measurements are strongly recommended. In a study of a 
mostly male population, reduced bone mineral density was 
significantly associated with particular HAART regimens. 
FRAX analysis of the entire population indicated a 1.2% 
increased risk of hip fracture and a 5.4% increased risk for 
major osteoporotic   fracture.17 Further FRAX analysis indi-
cated that there were 22 of 139 patients in the study (15.8%) 
who had a 17.5% increased risk of major osteoporotic fracture 
and three patients (2.2%) who had a 120% increased risk of 
major fracture.
Perturbation in the function of either osteoblasts or osteo-
clasts can result in bone density loss, presenting clinically 
as osteopenia or osteoporosis. Osteoporosis occurs during 
aging and is commonly associated with women follow-
ing menopause (on average at age 51 years), where it is 
called postmenopausal osteoporosis, but it can also occur 
in men or anyone with certain hormonal disorders, other 
chronic diseases, or as a result of medications such as 
glucocorticoids.19–25
HIV infection as a risk factor  
for bone health
There is clearly a large body of literature implicating a number 
of general factors associated with low bone mineral density 
in the general population, in particular those aged 50 years 
and older.26–29 One in two women and one in five men over 
the age of 50 years are expected to suffer a bone fracture due 
to osteoporosis during their remaining lifetime.30 A current 
question that requires much more intensive investigation 
is whether HIV infection is a risk factor for low mineral 
density and the mechanisms involved. For HIV-infected 
individuals, HIV infection has been implicated as a risk 
factor for alteration of bone mineral density.31–34 Clearly, 
there are general effects of HIV infection that can be risk 
factors for low bone mineral density. These include a low Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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body mass index, physical inactivity, malabsorption, and 
hypogonadism (Table 1). The HIV-infected population has 
been reported as having high rates of vitamin D deficiency, 
smoking, and drug and alcohol abuse, which are general risk 
factors for osteoporosis (Table 1).35 Immune cells may also 
influence bone mineral density.36 The loss of both immuno-
competence and bone mineral density are common during 
aging. Importantly, both are associated with HIV infection 
and AIDS pathogenesis, and in some respects can resemble 
accelerated aging.37 It is plausible that HIV infection could 
therefore accelerate the aging process.38
Mechanistic details regarding how HIV infection may 
reduce bone mineral density are quite limited, with minimal 
follow-up and demonstration of clearly identified   mechanisms. 
However, the limited literature would support the general 
model that HIV infection could impact the immune system, 
which would then influence the skeletal system.
During aging, the reduction in T cell renewal along with 
the progressive enrichment of terminally differentiated 
T cells results in a general decline of the immune system, 
leading to immunosenescence. Inflammation is a clear hall-
mark of age-associated comorbidities, and immune activation 
is a well established hallmark of HIV infection.39 Constant 
stimulation of the immune system by HIV can activate the 
innate and adaptive immune system. This activation results 
in the release of the mediators of inflammation, eg, cytokines. 
HIV-mediated immune activation, along with lack of anti-
inflammatory responses, is a likely driver of accelerated aging 
as a result of HIV infection, even during HAART-suppressed 
HIV replication. Age-associated defects have been observed 
in the activation of cells in the innate immune system.40 
Aging is characterized by a constitutive proinflammatory 
environment in which persistent low-grade innate immune 
activation could enhance cellular, tissue, and organ damage 
by HIV infection, including that of the skeletal system.
Osteoimmunology is an interdisciplinary research area 
that studies the interface and cross-talk between the skeletal 
and immune systems.41,42 In particular, osteoimmunology 
focuses on the shared components and mechanisms between 
the two systems, which include ligands, receptors,   signaling 
molecules, and transcription factors. Bone marrow is impor-
tant for the proper development of the immune system, and 
has important stem cells that maintain the immune system. 
Cytokines produced by immune cells (eg, RANKL, mac-
rophage colony-stimulating factor, tumor necrosis factor 
alpha [TNF-α], interleukins, and interferons) can also have 
important effects on regulating bone homeostasis. The bal-
ance between bone modeling and remodeling can be per-
turbed during chronic inflammation, which can lead to bone 
metabolic disorders as well as bone pain.
Some of the available literature shows a preliminary con-
nection between HIV infection and osteoimmunology. For 
example, it has been suggested that there is an association 
between chronic inflammatory conditions and osteoporosis, 
and that RANKL is produced by activated T cells, although 
no studies have provided mechanistic details to support this 
suggestion.43 During the asymptomatic phase of HIV infec-
tion, levels of inflammatory cytokines, such as interleukin-1, 
interleukin-6, and TNF-α are increased, and these cytokines 
can also stimulate bone resorption.43 RANKL levels have 
been found to be higher in HIV-infected men and correlated 
with lower bone mineral density,44 although another study 
found that bone mineral density was not associated with 
soluble TNF receptor 2 levels.45 Well-controlled studies 
have not been performed to date to demonstrate a connection 
between altered expression of cytokines due to HIV infec-
tion and changes in bone mineral density. Such studies, 
particularly using well-defined animal models, would be 
important studies to perform in order to provide clear evi-
dence in support of a cytokine-HIV infection-bone mineral 
density connection. In Figure 1, a general model is proposed 
for how HIV infection is connected to bone mineral density 
loss via cell signaling. Future experiments are needed to test 
and refine this model.
A few other reports provide connections, the underlying 
mechanisms of which remain unclear and a model to associate 
viral infection with bone mineral density loss is not obvious. 
First, an older report suggested reduced bone formation and 
turnover in iliac crest biopsies,46 but no follow-up on these 
studies has confirmed these observations. Further studies 
suggest other possible interactions between HIV infection, 
TNF-α, and bone mineral density. In one report, TNF-α has 
been reported to mediate apoptosis of human osteoblasts 
in response to HIV gp120.47 If confirmed, this observation 
could be an important connection between HIV infection 
and osteoblasts. Another observation found that vitamin D 
Table  1  General  risk  factors  associated  with  human 
immunodeficiency virus infection to bone mineral density loss
General risk factors
Low body mass index
Physical inactivity
Malabsorption
Hypogonadism
Vitamin D deficiency
Smoking
Drug and alcohol abuseClinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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deficiency is common among HIV-infected individuals, and 
a suggestion is that inhibition of 1-alpha-hydroxylase by 
TNF-α may have contributed to this.48
In summary, imbalances in growth factors and cytokines 
could contribute to bone mineral density loss by increas-
ing bone resorption, as indicated in the model proposed in 
the Figure. However, it is clear that most of these data are 
  suggestive and correlative, and there remains a strong need 
for very careful examination of potential mechanisms that can 
directly link HIV infection to bone mineral density loss.49 The 
study of osteoimmunology in the context of HIV infection 
provides fertile ground for enhancing our understanding of 
the fundamental mechanisms that may connect HIV infection 
with bone metabolism.
HAART as a risk to bone health
Several of the drug classes that comprise HAART have 
been implicated as risk factors for low bone mineral density 
(Table 2). Several of the HIV protease inhibitors have been 
shown to alter bone mineral density.50 Recent gene expres-
sion profiling has indicated that exposure of osteoblastic 
cells to nelfinavir and ritonavir increases gene expression 
of the inflammatory cytokines, MCP-1, and   interleukin-8.51 
Protease inhibitors have also been suggested to inhibit 
1-alpha-hydroxylase, as well as to reduce 1,25(OH)2D 
levels, which could reduce bone mineral density.45 LRP5, a 
positive regulator of bone formation, is inhibited by protease 
inhibitors.51,52
Reverse transcriptase inhibitors are another class of 
anti-HIV drugs that have been implicated in bone metabo-
lism. For example, azidothymidine, a nucleoside reverse 
transcriptase inhibitor, has been suggested to stimulate 
osteoclastogenesis in vitro and reduce bone mineral density 
in mice.53 Some nucleoside reverse transcriptase inhibitors 
have been implicated in causing mitochondrial damage and 
dysfunction due to their cross-inhibition of mitochondrial 
DNA polymerase.51,53 This could be responsible for the raised 
lactate levels observed in some HIV-infected individuals who 
are on HAART, which has been associated with increased 
bone resorption.54 Efavirenz, a non-nucleoside reverse tran-
scriptase inhibitor, has been reported to reduce vitamin D 
levels by inducing hepatic enzymes.55
Some of the strongest data in support of the components 
of HAART being associated with bone mineral density 
reductions have been observed with tenofovir, a nucleotide 
reverse transcriptase inhibitor, and been reported in human 
adults.56 Increased bone resorption could cause a compensa-
HIV infection
IL-17
activated
T-cell
RANKL
osteoblast
RANKL
osteoclast
precursor
osteoclast
bone resorption
macrophage
inflammatory cytokines
(eg, IL-1, IL-6, TNF alpha)
Figure 1 Proposed model for how human immunodeficiency virus (HIV) infection 
is associated with bone mineral density loss. HIV can infect both activated T cells 
and macrophages. HIV-infected T cells express interleukin (IL)-17, which stimulates 
HIV-infected macrophages to produce inflammatory cytokines, including IL-1, IL-6, 
and tumor necrosis factor (TNF). The inflammatory cytokines can stimulate both 
osteoblasts and osteoclasts. HIV-infected activated T cells and osteoblasts produce 
rAnKL, which further stimulates osteoclastogenesis. Overproduction of osteoclast 
activity results in an imbalance in bone remodeling and increases bone resorption.
Table 2 Drug classes in highly active antiretroviral therapy that 
have been implicated as risk factors for bone mineral density
Drug type
Protease inhibitors
nucleoside/nucleotide reverse transcriptase inhibitors
non-nucleoside reverse transcriptase inhibitorsClinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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tory increase in osteoblast activity, which would be revealed 
by increased serum alkaline phosphatase levels.57 Tenofovir 
treatment decreased bone mineral density, as well as increased 
urinary calcium excretion. Previous studies in macaques have 
demonstrated adverse effects on bone mineral density from 
the administration of tenofovir.58–60 Simian immunodeficiency 
virus infection of macaques was also implicated in decreas-
ing bone mineral density. Histomorphometric analysis in one 
of these studies revealed an increase in tibial osteoid seam 
width, which can result in bone softening and can develop 
into osteomalacia.58 The increase in osteoid seam width is 
likely to be associated with reduced activity in osteoblasts.
The gene expression profile of primary osteoclasts and 
osteoblasts has been evaluated ex vivo following tenofovir 
exposure.61,62 Specific downregulation of Gnas, Got2, and 
Snord32a was observed in osteoclasts. The downregulation 
of Gnas gene expression may result in less mitogen-activated 
protein kinase/extracellular signal-regulated kinase signal-
ing and ultimately a reduction in osteoclast proliferation 
and actin filament formation, resulting in decreased bone 
resorption. Got2 is a mitochondrial enzyme involved in 
energy transduction, specifically amino acid metabolism as 
well as the urea and tricarboxylic acid cycles. Perturbation 
of amino acid metabolism following exposure to tenofovir in 
both osteoblasts and osteoclasts suggests alteration in bone 
homeostasis. Over 70 genes had their gene expression altered 
in primary osteoblasts following tenofovir exposure. The 
changes in gene expression profiles involved in cell signaling, 
cell cycle, and amino acid metabolism, would likely impact 
osteoblast function in bone formation.
The association of tenofovir with mitochondrial dysfunc-
tion has been investigated. In general, no mitochondrial dys-
function was observed with tenofovir.63–66 Other studies have 
reported a lowering of mitochondrial dysfunction when drug 
regimens were changed and nucleoside reverse transcriptase 
inhibitors were replaced with tenofovir.67–69 Potential mecha-
nisms for tenofovir-associated bone loss include preferential 
uptake by osteoclasts (altering gene expression resulting in 
increased bone resorption), uptake by osteoblasts (altering 
gene expression decreasing bone formation), and uptake by 
both osteoclasts and osteoblasts (altering gene expression 
of both cells types and ultimately the balance between bone 
resorption and bone formation, resulting in bone loss).70 
The loss of bone density due to tenofovir exposure could 
also be associated with tenofovir-induced renal dysfunc-
tion, particularly renal proximal tubule dysfunction.17,57,71–79 
The failure of renal proximal tubular cells to reabsorb 
filtered bicarbonate from urine would result in urinary 
bicarbonate wasting and subsequent acidemia and a more 
general dysfunction of the proximal tubular cell, a clinical 
condition called Fanconi syndrome. Commonly observed 
clinical features in Fanconi syndrome include aminoaciduria, 
glycosuria, tubular proteinuria, and uricosuria. Importantly, 
the main pathology observed in Fanconi syndrome is bone 
demineralization (osteomalacia or rickets) due to phosphate 
wasting. Therefore, tenofovir-associated bone density loss 
may be an outcome of renal dysfunction.
Treatment of bone mineral density 
loss from HIV infection and HAART
The treatment of low bone mineral density requires a 
complete investigation into its etiology. Secondary causes 
and complications, particularly relevant for individuals 
50 years of age and older, including chronic liver disease, 
chronic malnutrition, hyperthyroidism, hypogonadism, and 
Type 1   diabetes, require identification and treatment where 
possible.80–82 Low vitamin D levels should be followed up by 
analysis of parathyroid hormone, with the goal of attempt-
ing to normalize vitamin D and parathyroid hormone levels. 
Diagnosis of osteoporosis, which would typically be estab-
lished by a T score , 2.5 for those 50 years of age and older, 
would warrant treatment with bisphosphonates in conjunction 
with vitamin D, calcium supplementation, and strategies 
geared towards trying to minimize the risk of falls.
Bisphosphonates are synthetic analogs of inorganic 
pyrophosphate.83–85 They inhibit bone resorption by increas-
ing the apoptosis of osteoclasts. To date, preliminary data 
suggest that the use of bisphosphonates is effective in increas-
ing bone mineral density in the presence of HAART.86–88 The 
bisphosphonates, including alendronate (Fosamax®), iban-
dronate (Boniva®), risedronate (Actonel®), and zoledronate 
(Aclasta®, Zometa®) are all available as options for use in the 
treatment of bone mineral density loss.83–85 There are concerns 
regarding the use of bisphosphonates in the treatment of bone 
mineral density loss that occurs in HIV-infected individuals. 
One major concern is that the oral administration of bispho-
sphonates requires a very complex dosing regimen, ie, the 
bisphosphonate must be taken fasting, with the individual 
sitting or standing, with a large glass of water, and then 
the individual must remain upright for 30–60 minutes after 
taking the medication, without eating or drinking or taking 
other medications during that time. Another concern is the 
long-term administration of bisphosphonates in the context 
of HIV infection and HAART. To date, alendronate has been 
the most extensively used bisphosphonate in the treatment of 
bone mineral density loss in the context of HIV infection.89,90 Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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However, there has not been enough statistical power in the 
relevant research to conclude that fracture rates are lowered. 
This should be a priority of future clinical studies.
Conclusion
The specific role(s) of HIV infection in bone mineral loss 
remains poorly characterized, and further studies are needed 
to identify the underlying mechanisms. The use of appropriate 
animal models would be highly desirable in this regard. The 
role of specific HAART regimens in increased risk of bone 
mineral density loss has been suggested but not fully analyzed, 
particularly in the context of many of the newly approved anti-
HIV drugs available. Further studies are needed to investigate 
whether declines in bone mineral density are greater in indi-
viduals over 50 years of age receiving HAART compared with 
the non-HIV-infected population to aid further in identifying 
potential risk factors.91 The rate of bone mineral density loss 
is an important parameter to determine in the identification of 
possible treatments using bisphosphonates. A relatively slow 
decline in bone mineral density loss could allow for bisphos-
phonates, such as zoledronate, to be used as an adjuvant therapy 
along with HAART. Given that the HIV-infected population 
is aging and many patients are now reaching the age of 50 
years, there needs to be serious consideration of the impact 
of HIV infection and HAART on the health of those affected, 
particularly in the area of bone health.
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